25, 2025 /PRNewswire/ -- Akston, the Biotech Built for Pets, announced today the start of a clinical study at Cornell University College of Veterinary Medicine to evaluate its once-weekly GLP-1 weight-management therapy for cats
Suitable candidate Adults seeking nad+ iv therapy for general tiredness, brain fog, low day-to-day energy Patients in good general health with realistic expectations Patients who can attend a doctor-led consultation before treatment Not suitable for Pregnancy or breastfeeding Active skin infection or open wound in the treatment area Recent sunburn or active dermatitis Known allergy to any product used during the treatment Certain medical conditions or medications disclosed at consultation Risks & side effects Every medical procedure carries some risk
Beyond the Scale: Physical and Metabolic Changes The scale weight tells one story
This can cause them to lose weight quickly at first, but it might not be sustainable over time
Fully achieved reduction of severe lesions in the brain, heart, lungs, liver, kidneys, and gastrointestinal tract reduced thrombosis in both veins and arteries, peripherally and centrally, and fully abrogated intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension may be regarded as a proof of concept
Combining retatrutide with insulin or sulfonylureas significantly increases the risk of hypoglycaemia and may require dose adjustments